A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Patients With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
Latest Information Update: 14 Aug 2024
At a glance
- Drugs Atezolizumab (Primary) ; Carboplatin (Primary) ; Cisplatin (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary) ; Pemetrexed (Primary) ; Tiragolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms SKYSCRAPER-05
- Sponsors Roche
- 05 Oct 2023 Status changed from recruiting to active, no longer recruiting.
- 29 Sep 2023 This trial has been completed in Poland.
- 18 Jan 2023 Planned End Date changed from 28 Feb 2027 to 30 Apr 2028.